Testing the clinical utility of combining existing agents is feasible, particularly in neoplasms in which LSD1 inhibition has already shown signs of efficacy, like AMLs and neuroendocrine tumors including challenging contexts like SCLC. Here, KDM1A is linked to neuroendocrine neoplasm.